These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Lahlou S; Lima GC; Leão-Filho CS; Duarte GP Can J Physiol Pharmacol; 2000 Mar; 78(3):260-5. PubMed ID: 10721819 [TBL] [Abstract][Full Text] [Related]
8. Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors. Lahlou S; Duarte GP Fundam Clin Pharmacol; 1998; 12(6):599-606. PubMed ID: 9917201 [TBL] [Abstract][Full Text] [Related]
10. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution]. Chamontin B; Montastruc JL; Rascol A Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826 [TBL] [Abstract][Full Text] [Related]
11. Effects of verapamil on ventricular tachycardia induced by ouabain in guinea pigs. Goldberger JJ; Aronson RS Pacing Clin Electrophysiol; 1992 Feb; 15(2):162-70. PubMed ID: 1372415 [TBL] [Abstract][Full Text] [Related]
12. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits. Ensinger H; Majewski H; Hedler L; Starke K J Pharmacol Exp Ther; 1985 Sep; 234(3):681-90. PubMed ID: 2993590 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Na+/Ca2+ overload with R 56,865 protects against cardiac arrhythmias elicited by ouabain in vivo in guinea-pigs. Lu HR; Remeysen P; De Clerck F Eur J Pharmacol; 1993 Apr; 235(1):89-93. PubMed ID: 8519283 [TBL] [Abstract][Full Text] [Related]
14. [Hypotensive action of a dopaminergic agonist, bromocriptine, in the dog]. Montastruc JL; Rascol A; Montastruc P Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():91-8. PubMed ID: 6794532 [TBL] [Abstract][Full Text] [Related]
15. Contribution of spinal dopamine receptors to the hypotensive action of bromocriptine in rats. Lahlou S; Demenge P J Cardiovasc Pharmacol; 1991 Sep; 18(3):317-25. PubMed ID: 1720830 [TBL] [Abstract][Full Text] [Related]
16. R56865, an antiarrhythmic drug with class III effects that terminates ouabain induced ventricular tachycardia in an inverse rate dependent manner. Vos MA; van Deursen RT; Gorgels AP; Leunissen JD; Wellens HJ Cardiovasc Res; 1993 Aug; 27(8):1491-7. PubMed ID: 8221803 [TBL] [Abstract][Full Text] [Related]
17. Relationship between heart rate and ouabain toxicity in the dog heart-lung preparation. Lahiri PK; Laddu AR Jpn Heart J; 1973 Jul; 14(4):357-65. PubMed ID: 4542950 [No Abstract] [Full Text] [Related]
18. Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats. Lahlou S; Araújo Lima PF; Interaminense LF; Duarte GP Pharmacol Toxicol; 2003 Apr; 92(4):189-94. PubMed ID: 12753422 [TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic and hemodynamic effects of an aminosteroid (Org 3001) in the digitalized dog. Remme WJ; Verdouw PD; Hagemeyer F Eur J Pharmacol; 1976 Mar; 36(1):189-97. PubMed ID: 1261591 [TBL] [Abstract][Full Text] [Related]
20. Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects. Sintov A; Scott WA; Gallagher KP; Levy RJ Pharm Res; 1990 Jan; 7(1):28-33. PubMed ID: 2300532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]